The U.S. Supreme Court rejects Tata’s challenge to a $168 million trade secrets damages award in a dispute involving DXC, a company based in Ashburn, Virginia. According to reports, the case traces back to a lower-court decision that had affirmed a judge’s damages ruling. That ruling set compensatory damages at $56 million and punitive damages at $112 million. Tata had appealed the award after the lower court upheld the judge’s decision. With the Supreme Court declining to grant relief, the damages award remains in place. The reporting across outlets focuses on the Supreme Court’s decision to not entertain or overturn Tata’s challenge, leaving the underlying judgment and the split between compensatory and punitive damages unchanged. The matter continues to reflect how U.S. courts handle trade secrets claims and the availability of punitive damages when a court finds a sufficient basis under applicable law. The sources cited do not indicate additional changes to liability or facts beyond the Supreme Court’s refusal to disturb the award.
U.S. Supreme Court rejects Tata bid to overturn $168 million trade secrets award
The U.S. Supreme Court rejects Tata’s challenge to a $168 million trade secrets damages award in a dispute involving DXC, a company based in Ashburn, Virginia. According to reports, the case traces ba...
- The U.S. Supreme Court rejects Tata’s challenge to a trade secrets damages award.
- The total award is $168 million.
- The award includes $56 million in compensatory damages.
- The award includes $112 million in punitive damages.
- DXC is an Ashburn, Virginia-based company involved in the dispute.
Tata had appealed after a lower court upheld a judge's decision to set the award at $56 million in compensatory damages and $112 million in punitive damages to Ashburn, Virginia-based DXC
12 hours ago
Asian markets mostly rise as Japan’s Nikkei briefly tops 70,000 after BOJ rate hike
Asian stock markets trade mostly higher as investors react to a Bank of Japan (BOJ) interest-rate decision. Japan’s benc...
Analysts downgrade Roku stock ratings ahead of Fox acquisition
Multiple analysts downgrade their ratings on Roku following the company’s planned acquisition involving Fox. According t...
Adaptive Biotechnologies and Abeona Therapeutics file Form 144 notices
On 15 June, Adaptive Biotechnologies Corporation and Abeona Therapeutics Inc. file Form 144 notices. Form 144 is a filin...